Rigshospitalet
Department of Radiation Biology

Signe Regner Michaelsen, M.Sc.

Email: signe.regner.michaelsen@regionh.dk
Phone: (+45) 35 45 63 27
Fax: (+45) 35 45 63 01

Place and Date of Birth:

August 7nd, 1985

Current Position:
PhD student
 
Research and Professional Experiences:
2014-PhD student at the Department of Radiation Biology, Rigshospitalet, Denmark.
2011-2014Research Assistant at the Department of Radiation Biology, Copenhagen University Hospital, Denmark
2009-2011Masters thesis at the Department of Radiation Biology, Copenhagen University
Hospital, Denmark.
2008:Bachelor thesis at the Department of Molecular Biology, University of
Copenhagen, Denmark: “Analysis of the WISP-2 expression in transformed and
non-transformed mouse fibroblasts”.
 
Education:
2009-2011Master student, Molecular Biomedicine, University of Copenhagen, Denmark
2005-2008Bachelor student, Molecular Biomedicine, University of Copenhagen, Denmark
2001-2004High School, Allerød Gymnasium, Denmark
 
 Authorizations:
1.Radioactive isotopes and ionizing radiation: Authorization for persons responsible for
biological (non-clinical) application of radioactive tracers.
2.Laboratory Animal Science: Authorization to perform experiments on live animals
 
Awards, Grants and Scholarships:
2010Granted a 1-year student scholarship from the Danish Cancer Society
2012Granted a travel grant from Danmarks Lungeforening
2012Granted a Travel grant from Rigshospitalets Fond for Onkologiske Formål.
2012Granted a rechearch grant from Dansk Kræftforsknings Fond.
2013Granted a Travel grant from Kræftens Bekæmpelse.
2013Granted a research grant from Arvid Nilsson’s fond.
2014Granted a 3-year PhD. scholarship from the Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
2014Granted a Travel grant from Rigshospitalets Fond for Onkologiske Formål.
2015Granted a research grant from Dansk Kræftforsknings Fond.

 
Conferences and Meetings:
Poster presentation
2010The 23th annual Meeting of the Danish Association for
Cancer Research, Charlottenlund, Denmark:Michaelsen SR,  Christensen CL, Poulsen TT, Sehested M, Cramer F and Poulsen HS; “Resistance to common
chemotherapeutic agents do not influence the cytotoxic effects of suicide gene
therapy in small cell lung cancer cell lines
2011The 24th annual Meeting of the Danish Association for
Cancer Research, Charlottenlund, Denmark:  Michaelsen SR ,Christensen CL, Poulsen TT,  Sehested M, Cramer F and Poulsen HS; “The sensitivity of small cell lung cancer cells to suicide gene therapy is independent of resistance to common chemotherapeutic agents”.
2012The 25th annual Meeting of the Danish Association for Cancer Research, Charlottenlund, Denmark: Michaelsen SR, Christensen CL, Sehested M, Cramer F, Poulsen TT and  Poulsen HS; “Suicide gene therapy is effective for treating chemo-resistant small cell lung cancer cells”.
2012The Symposium for Young Scientific Investigators at Copenhagen University Hospital (FYF), Copenhagen, Denmark: Michaelsen SR, ChristensenCL, Sehested M, Cramer F, Poulsen TT and  Poulsen HS; “Suicide gene therapy is effective for treating chemo-resistant small cell lung cancer cells”.
2012The 103th Annual American Association for Cancer Research (AACR), Chicago, Illinois, USA: Michaelsen SR, Christensen CL,  Sehested M, Cramer F,  Poulsen TT and Poulsen HS; “Suicide gene therapy is effective for treating chemo-resistant small cell lung cancer cells”.
2013
The EORTC-EANO-ESMO Conference 2013, Prague, Czech Republique: Michaelsen SR, Christensen IJ, Grunnet K, Stockhausen M-T, Broholm H, Kostaljanetz M, Poulsen HS;
“A model for survival from glioblastoma multiforme in a cohort of consecutive non-selected patients from a single institution”.
2013The 26th annual Meeting of the Danish Association for Cancer Research, Charlottenlund, Denmark: Michaelsen SR, Christensen IJ, Grunnet K, Stockhausen M-T, Broholm H, Kostaljanetz M, Poulsen HS; A model for survival from glioblastoma multiforme in a cohort of consecutive non-selected patients from a single institution
2013The 4th Quadrennial Meeting of the World Federation of Neuro-Oncology and The18th Annual SNO Scientific Meeting and Education Day, San Francisco, Californien, USA :Michaelsen SR, Stockhausen ST, Pedersen P, Nedergaard MK and  Poulsen HS;"VEGFA independent activation of VEGFR2 in Glioblastoma Multiforme cells".
2014The 11th EANO 2014 meeting, Turin, Italy: Michaelsen SR, Nedergaard MK, Villingshoej M, Pedersen P, Stockhausen MT, and Poulsen HS: "Autocrine VEGFC-VEGFR2 signaling is of importance for the growth of Glioblastoma Multiforme.”
2015The Annual American Association for Cancer Research (AACR), Philadelphia, Pennsylvania, USA: Michaelsen SR, Nedergaard MK, Urup T, Olsen LR, Kjær A, Perryman L, Erler JT, Lassen U and Poulsen HS; "The role of VEGFC for cell viability, tumor growth and bevacizumab resistance in Glioblastoma Multiforme
2015
The 20th Annual SNO Scientific Meeting and Education Day, 2015 San Antonio, USA: Michaelsen SR, Nedergaard MK,,Broholm H, Urup T, Aghi M, Lukacova S, Staberg M, Villingshøj M, Kjær A, Perryman L, Erler JT, Lassen U, Stockhausen MT, Poulsen HS, Hamerlik P; VEGF-C contributes to autocrine VEGFR2 signaling and affects cell viability and tumor growth in glioblastoma.
2017Urup T, Staunstrup LM, Michaelsen SR, Vitting-Seerup K, Bennedbæk M, Toft A, Olsen LR, Jønson L, Issazadeh-Navikas S, Broholm H, Hamerlik P, Poulsen HS, Lassen U. Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients. BMC Cancer. 2017 Apr 18;17(1):278. doi: 10.1186/s12885-017-3251-3. PMID: 28420326
 
Oral presentation:
2014The 27th annual Meeting of the Danish Association for
Cancer Research, Charlottenlund, Denmark: Michaelsen SR, Nedergaard MK, Pedersen P, Stockhausen M-T, Poulsen HS; “ Autocrine VEGFC-VEGFR2 signaling is of importance for the growth of Glioblastoma Multiforme”.
2015The XI Northern Lights Neuroscience Symposium on Brain Tumors, Hindsgavl, Middelfart: Michaelsen SR, Nedergaard MK, Villingshoej M, Perryman L, Erler JT, Lassen U, Stockhausen MT, Hamerlik P and Poulsen HS; "VEGFC is a regulator of autocrine VEGFR2 signaling, cell viability and tumor growth in glioblastoma."
2016Scandinavian Society of Neuro-Oncology Meeting, Copenhagen:  Michaelsen SR,Nedergaard M, Broholm H, Bartokova, Staberg M, Urup T, Aghi M, Lubacova S, Villingshøj M, Pedersen P, Kjær A, Perryman L, Erler J, Bartek J, Lassen U, Stockhausen MT, Poulsen HS, Hamerlik P; "VEGF-C contributes to autocrine VEGF Receptor 2 signaling and cellular maintenance in Glioblastoma"
 
Publications:
2012Michaelsen SR, Christensen CL, Sehested M, Cramer F, Poulsen TT, Patterson AV, Poulsen HS: Single agent- and combination treatment with two targeted gene therapy systems is effective in chemo-resistant small cell lung cancer (SCLC) cells. J Gene Med. Jul;14(7):445-58,
2013Michaelsen SR, Christensen IJ, Grunnet K, Stockhausen MT, Broholm H, Kostaljanetz M, Poulsen HS: Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme in a cohort of consecutive non-selected patients from a single institution. BMC Cancer. 2013 Sep 3;13(1):402.
2014Nedergaard MK, Kristoffersen K, Michaelsen SR, Poulsen HS, Stockhausen MS, Lasse U, Kjaer A: The use of longitudinal 18F-FET MicroPET imaging to evaluate response to irinotecan in orthotopic human glioblastoma multiforme xenografts. PLoS One. 2014; 9(6): e100009.
2014Poulsen HS, Urup T, Michaelsen SR, Staberg M, Villingshøj M, Lassen U: The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients. Cancer Manag Res.2014:6 373–387
2014Christensen CL, Kwiatkowski N, Abraham BJ, Carretero J, Al-Shahrour F, Zhang T, Chipumuro E, Herter-Sprie GS, Akbay EA,Altabef A, Zhang J, Shimamura T, Capelletti M, Reibel JB, Cavanaugh JD, Gao P, Liu Y, Michaelsen SR, Poulsen HS, Aref AR, Barbie DA,. Bradner JE, George RE, Gray NS, Young RA, Kwok-Kin Wong KK: Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor:Cancer Cell; Volume 26, Issue 6, 8 December 2014, Pages 909–922
2015Nedergaard MK, Michaelsen SR, Urup T, Broholm H, El Ali H, Poulsen HS, Stockhausen MT, Kjaer A and Lassen U: 18F-FET MicroPET and MicroMRI for anti-VEGF and anti-PlGF response assessment in an orthotopic murine model of human glioblastoma:PLoS One. 2015 Feb 13:10(2): e0115315.
2015Persson M, Nedergaard MK, Brandt-Larsen M, Skovgaard D, Jørgensen JT,Michaelsen SR, Madsen SR, Lassen U, Poulsen HS, Kjaer A: uPAR is a promising new imaging biomarker in Glioblastoma. J Nucl Med. 2015. J Nucl Med. 2015 Oct 1.
2015Urup T, Dahlrot RH, Grunnet K, Christensen IJ, Michaelsen SR, Toft A, Larsen VA, Broholm H, Kosteljanetz M, Hansen S, Poulsen HS, Lassen U: Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecants treated with bevacizumab and irinotecan: Acta Oncol 2015. Acta Oncol. 2016 Feb 1:1-5.
2015Kristensen LS, Michelsen SR, Dyrbye H, Aslan D, Grunnet K, Christensen IJ, Poulsen HS, Grønbæk K, Broholm H: Assessment of quantitative and allelic MGMT methylation patterns as a prognostic marker in glioblastoma.  J Neuropathol Exp Neurol. 2016 Feb 16
2016Nedergaard MK, Michaelsen SR, Perryman L, Erler, Poulsen HS, Lassen U, Stockhausen MT and Kjaer A. Comparison of 18F-FET and 18F-FLT MicroPET for the assessment of anti-VEGF efficacy in an orthotopic model of glioblastoma.  Nucl Med Biol. 2016 Mar;43(3):198-205.
2016Staberg M, Michaelsen SR, Olsen LS, Nedergaard MK, Villingshøj M, Hamerlik P, Poulsen HS:
Combined EGFR- and Notch inhibition display additive inhibitory effect on Glioblastoma cell viability
and Glioblastoma-induced endothelial cell sprouting in vitro. Cancer Cell Int.2016 Apr 26; 16:34. doi: 10.1186. PMID: 27118928
2016Urup T, Michaelsen SR, Rønn Olsen LR,Toft A, Christensen IJ, Grunnet K, Winther O, Broholm H, Kosteljanetz M, Issazadeh-Navikas S, Poulsen HS, Lassen U: Angiotensinogen and HLA Class II Predict Bevacizumab Response in Recurrent Glioblastoma Patients.Mol Oncol. 2016 Oct; 10(8):1160-8. doi: 10.1016. PMID: 27262894
2016Staberg M, Michaelsen SR, Rasmussen RD, Villingshøj M, Poulsen HS, Hamerlik P: Inhibition of histone deacetylases sensitizes glioblastoma cells to Lomustine. Cell Oncol (Dordr). 2016 Oct 20. PMID: 27766591

 Articles submitted:
2014Michaelsen SR, Nedergaard MK, Pedersen P, Broholm H, Kjær A, Perryman L, Singh LB, Erler TE, Lassen TE, Stockhausen MT, Poulsen HS: Vascular Endothelial Growth Factor (VEGF) C is a regulator of autocrine VEGF Receptor 2 signaling, cell viability and tumor growth in Glioblastoma Multiforme. Submitted.
2015Toft A, Urup T, Christensen IJ, Michaelsen SR, Lukram B, Grunnet K, Kosteljanetz M, Larsen AVA, Lassen U, Broholm H, Poulsen HS: Predictive and Prognostic Biomarkers in Recurrent WHO Grade III Glioma Patients Treated with Bevacizumab and Irinotecan. Submitted


 
 

 

 

 

The Finsencenter, Section 6321, Copenhagen University Hospital, Blegdamsvej 9, DK-2100 Copenhagen, Denmark